Merck and Moderna’s positive Phase 3 INTerpath-001 readout in August 2026, showing statistically significant gains in recurrence-free and distant metastasis-free survival for intismeran autogene (mRNA-4157/V940) plus pembrolizumab versus pembrolizumab alone in resected high-risk melanoma, forms the main catalyst behind current trader sentiment. This first successful late-stage result for an individualized neoantigen mRNA cancer vaccine builds on five-year Phase 2 data confirming durable benefit and has prompted the partners to schedule full data presentation at a medical meeting while beginning regulatory discussions on a potential BLA filing. Competitive pressure remains limited, as rival programs such as IO Biotech’s cylembio faced FDA pushback against immediate submission last year. Key near-term watchpoints include the timing of any pre-BLA meeting outcomes, manufacturing scale-up for personalized doses, and whether the companies pursue accelerated review given breakthrough therapy designation.